Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...

The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen ...

Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the ...

The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib ...

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors Chronic myelomonocytic leukemia ...

The research on bone-marrow transplantation mirrors the arc of many medical advancements. I was one of the early ...

A once-dismissed idea that a single pill could stop cancer now shapes how doctors treat the disease. This week, Oregon Health ...

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia ...